Managers

LACERS acts on $185 mln in recommendations by former PE consultant

Year in Review: ICO hoopla fades after 2018 fundraising spikes

Tusk Ventures to raise $70 mln second venture-capital fund

Tusk Ventures has set out to raise a $70 million second venture-capital fund, according to a filing with the SEC.

VC Arlan Hamilton had no VC experience but has now backed 100 companies

Third Kind Venture Capital targets $65 mln for sophomore fund

Third Kind Venture Capital is seeking to raise $65 million for its second fund, according to an SEC filing. The New York-based venture firm is focused on early-stage investments.

Medication guidance company WithMe Health rakes in $20 mln

Boston-based WithMe Health, a medication guidance company, has raised $20 million in financing. The investor was Oak HC/FT.

Pear Therapeutics locks in $64 mln Series C

Boston and San Francisco-based Pear Therapeutics, a provider of prescription digital therapeutics, has secured $64 million in Series C financing. Temasek led the round with participation from other investors that included Novartis, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, The Bridge Builders Collaborative, EDBI, Blue Water Life Science Fund LP and Trustbridge Partners.

Ribon Therapeutics lands $65 mln Series B

Lexington, Massachusetts-based Ribon Therapeutics, a biotechnology company, has raised $65 million in Series B financing. Novartis Venture Fund led the round with participation from JJDC, Celgene Corporation, The Column Group, Deerfield Management, U.S. Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital.

Swiss health tech company Sophia Genetics picks up $77 mln

Sophia Genetics, a Swiss health tech company, has raised $77 million in funding. Generation Investment Management led the round with participation from other investors that included Idinvest Partners, Balderton Capital and Alychlo.

Oculis nets about $15.6 mln

Oculis, a Swiss developer of ophthalmic drugs, has raised CHF 15.5 million (about $15.6 million) in funding. Tekla Capital Management LLC led the round with participation from other investors that included Nan Fung Life Sciences.